Pitavastatin

Synonymes : Pitavastatin, 147526-32-7, Itavastatin, NK-104, (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid

Pitavastatin is a fully synthetic HMG-CoA reductase inhibitor featuring a quinoline core bearing a cyclopropyl group at the 2-position and a 4-fluorophenyl substituent at the 4-position. The (3R,5S,6E)-3,5-dihydroxy-6-heptenoic acid side chain is essential for binding to the enzyme’s active site, while the lipophilic quinoline system enhances interaction with the enzyme’s hydrophobic pocket.

Unlike many statins that rely on microbial fermentation, pitavastatin is produced through multi-step organic synthesis, ensuring high purity and consistent supply. It is available as the free acid or as various salts, such as pitavastatin calcium and pitavastatin magnesium, each with distinct solubility profiles and bioavailability characteristics. The compound is typically manufactured under cGMP conditions and meets stringent quality standards for pharmaceutical use.

As a potent lipid-lowering agent, pitavastatin is primarily used in the treatment of hypercholesterolemia and mixed dyslipidemia. Its unique structure confers metabolic stability and minimal interaction with cytochrome P450 enzymes, making it a valuable option in clinical practice. Beyond its approved indications, pitavastatin is investigated for pleiotropic effects, including plaque stabilization and anti-inflammatory actions, driving demand for high-quality API in research and formulation development.

Structure chimique et propriétés

The molecular structure of pitavastatin comprises a quinoline ring system substituted with cyclopropyl and 4-fluorophenyl groups, linked to a chiral 3,5-dihydroxy heptenoic acid side chain. This configuration yields a molecular weight of 421.46 g/mol and a logP value of approximately 4.5, indicating moderate lipophilicity. The compound is a white to off-white crystalline powder, soluble in organic solvents such as methanol and ethanol, but practically insoluble in water. Its crystalline form and stereochemistry are critical for biological activity, and stringent control of chiral purity is maintained during synthesis.

Mécanisme d'action

• HMG-CoA reductase inhibition: Competitively inhibits the rate-limiting enzyme in the mevalonate pathway, reducing cholesterol biosynthesis in the liver.
• Upregulation of LDL receptors: Decreases intracellular cholesterol, triggering increased expression of hepatic LDL receptors and enhanced clearance of LDL-C from the bloodstream.
• Pleiotropic effects: Modulates endothelial function, reduces vascular inflammation, and stabilizes atherosclerotic plaques, contributing to cardiovascular risk reduction.
• Metabolic stability: The cyclopropyl and fluorophenyl groups hinder metabolism by cytochrome P450 enzymes, particularly CYP3A4, resulting in fewer drug-drug interactions compared to other statins.

Spécifications de qualité

Approvisionnement et documentation

• Capacité: Annual production capacity of 5 metric tons, with scalable campaigns to meet large-volume orders.
• Délai de livraison: 3 à 5 jours ouvrés (articles en stock)
• Documentation: Comprehensive documentation including Certificate of Analysis (COA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and regulatory support files (e.g., DMF).
• Emballage: Standard 25 kg fiber drums with double polyethylene liners; custom packaging configurations available to suit specific handling and storage requirements.

Demande de devis

• LyvBio Co. — E-mail : info@lyvbio.com